In: Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, vol. 388, no. 1, p. 43-49
|
In: The Journal of Infectious Diseases, 2016, vol. 213, no. 9, p. 1370-1379
|
In: European Journal of Pediatrics, 2015, vol. 174, no. 9, p. 1255-1262
|
In: European Journal of Medicinal Chemistry, 2020, vol. 205, p. 112533
We have prepared a series of ten 3-arylcoumarin molecules, their respective fac- [Re(CO)3(bpy)L]+ and fac-[Re(CO)3(L⁀L)Br] complexes and tested all compounds for their antimicrobial efficacy. Whereas the 3-arylcoumarin ligands are virtually inactive against the human-associated pathogens with minimum inhibitory concentrations (MICs) > 150 μM, when coordinated to the fac-[Re(CO)3]+ core,...
|
In: European Journal of Clinical Microbiology & Infectious Diseases, 2014, vol. 33, no. 11, p. 1967-1971
|
In: International Orthopaedics, 2014, vol. 38, no. 11, p. 2323-2327
|
In: International Orthopaedics, 2014, vol. 38, no. 6, p. 1283-1290
|
In: European Journal of Clinical Microbiology and Infectious Diseases, 2006, vol. 25, no. 8, p. 535-536
|
In: European Journal of Clinical Microbiology & Infectious Diseases, 2012, vol. 31, no. 12, p. 3367-3374
|
In: Clinical Oral Investigations, 2009, vol. 13, no. 4, p. 369-373
|